{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HR%2B%2FHER2%2B+Breast+Cancer", "query": { "condition": "HR+/HER2+ Breast Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 192, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HR%2B%2FHER2%2B+Breast+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T04:42:29.222Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07492641", "title": "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HR+/HER2- Breast Cancer" ], "interventions": [ { "name": "BGB-43395", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1056, "start_date": "2026-05-22", "completion_date": "2037-08-07", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07492641" }, { "nct_id": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Epithelial Ovarian Cancer", "High Grade Serous Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Non-small Cell Lung Cancer", "Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)", "Mesothelioma", "Breast Adenocarcinoma", "Triple Negative Breast Cancer", "Hormone Receptor-positive/Her2 Negative Breast Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Platinum Sensitive Ovarian Cancer (PSOC)", "Primary Refractory Ovarian Cancer", "Uterine Cancer" ], "interventions": [ { "name": "Rina-S", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 884, "start_date": "2022-12-07", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579366" }, { "nct_id": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "HR+/HER2- Breast Cancer", "HR+, HER2-, Advanced Breast Cancer", "CCNE1 Amplification", "Epithelial Ovarian Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Endometrial Cancer", "TNBC - Triple-Negative Breast Cancer" ], "interventions": [ { "name": "AVZO-021", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Sacituzumab Govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avenzo Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 430, "start_date": "2023-08-30", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 11, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Mineola", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867251" }, { "nct_id": "NCT07198724", "title": "ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "HER2 Low Breast Carcinoma", "HER2-negative Breast Cancer", "Breast Cancer", "Breast Cancer Female" ], "interventions": [ { "name": "Elacestrant", "type": "DRUG" }, { "name": "Trastuzumab Deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kristina A. Fanucci", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2025-11-17", "completion_date": "2038-06-01", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07198724" }, { "nct_id": "NCT04215146", "title": "A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer Metastatic" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pelareorep", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Oncolytics Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 48, "start_date": "2020-06-10", "completion_date": "2025-06", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 18, "location_summary": "Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04215146" }, { "nct_id": "NCT05191004", "title": "Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer", "Breast Cancer", "Breast Carcinoma", "Cancer of the Breast", "Cancer of Breast", "Malignant Tumor of Breast", "Breast Tumor" ], "interventions": [ { "name": "NUV-422", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-09", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2023-07-11", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 5, "location_summary": "Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Canton", "state": "Ohio" }, { "city": "Gettysburg", "state": "Pennsylvania" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05191004" }, { "nct_id": "NCT02278120", "title": "Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "59 Years", "sex": "FEMALE", "summary": "18 Years to 59 Years · Female only" }, "enrollment_count": 672, "start_date": "2014-11-20", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 35, "location_summary": "Bakersfield, California • Los Angeles, California • Denver, Colorado + 29 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Danbury", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02278120" }, { "nct_id": "NCT07223476", "title": "Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1926, "start_date": "2024-03-29", "completion_date": "2024-07-01", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223476" }, { "nct_id": "NCT02692755", "title": "Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "Palbociclib + Letrozole or Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2016-09", "completion_date": "2021-03-23", "has_results": true, "last_update_posted_date": "2021-09-28", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02692755" }, { "nct_id": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Malignant Solid Tumors" ], "interventions": [ { "name": "enfortumab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2020-03-10", "completion_date": "2026-09-30", "has_results": true, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-07-23T04:42:29.222Z", "location_count": 29, "location_summary": "Tucson, Arizona • San Francisco, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04225117" } ] }